Effectiveness and safety of CT-guided 125I seed brachytherapy for postoperative locoregional recurrence in patients with non–small cell lung cancer

Huo, Xiaodong; Wang, Huixing; Jingkui, Yang; Yan, Wei; Huo, Bin; Zheng, Guangjun; Chai, Shude; Wang, Junjie; Guan, Zhiwei; Yu, Zutao

doi:10.1016/j.brachy.2016.02.001

Cited by 28 publications

(22 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, although ultrasound (US) is commonly used in LDR brachytherapy of prostate cancer, US is an unusual method for lung brachytherapy . These approaches have taken LDR brachytherapy to a new level in controlling the dose and achieving improved accuracy of the needle arrangement, and good clinical outcomes have been obtained Since the outcomes of LDR brachytherapy depend on the accuracy of the placement of needles and seeds, an effective and visualized guidance system is required to ensure that needles and seeds are implanted precisely into the target regions. Many studies have focused on improving the accuracy of implanting seeds during surgery using an image‐guided system …”

Section: Introductionmentioning

confidence: 99%

Design and validation of a surgical navigation system for brachytherapy based on mixed reality

et al. 2019

View full text Add to dashboard Cite

Purpose An accurate position of the needle is vitally important in low‐dose‐rate seed implantation brachytherapy. Our paper aims to implement a mixed reality navigation system to assist with the placement of the I125 seed implantation thoracoabdominal tumor brachytherapy needle and to validate the accuracy and quality of this type of method. Methods With the surgical navigation system, based on mixed reality through a novel modified multi‐information fusion method, the fusion of virtual organs and a preoperative plan for a real patient and the tracking of surgical tools in real time were achieved. Personalized image recognition and pose estimation were used to track needle punctures in real time and to perform registration processes. After a one‐time registration with a hexagonal prism tracker that used an iterative closest point algorithm, all information, including medical images and volume renderings of organs, needles, and seeds, was precisely merged with the patient. Doctors were able to observe the tumor target and to visualize the preoperative plan. This system was validated in both phantom and animal experiments. The accuracy of this system was validated by calculating the positional and rotational error of each needle insertion. The accuracy of implantation of each seed was determined in an animal experiment to test the accuracy in low‐dose‐rate brachytherapy. The efficiency of this system was also validated through time consumption assessments. Results In the phantom experiment, the average error of the needle locations was 0.664 mm and the angle error was 4.74°, average time consumption was 16.1 min with six needles inserted. Based on the results of the animal experiment, the accuracy of the needle insertion was 1.617 mm, while the angle error was 5.574° and the average error of the seed positions was 1.925 mm. Conclusions This paper describes the design and experimental validation of a novel surgical navigation system based on mixed reality for I125 seed brachytherapy for thoracoabdominal tumors. This system was validated through a series of experiments, including phantom experiments and animal experiments. Compared with the traditional image‐guided system, the procedure presented here is convenient, displays clinically acceptable accuracy and reduces the number of CT scans, allowing doctors to perform surgery based on a visualized plan. All the experimental results indicated that the procedure is ready to be applied in further clinical studies.

show abstract

Section: Introductionmentioning

confidence: 99%

Design and validation of a surgical navigation system for brachytherapy based on mixed reality

et al. 2019

View full text Add to dashboard Cite

show abstract

“…prostate and lung cancers. 13,25 Chen et al 26 first reported the use of a 125 I seeds strand in the pig bile tract, assessing technical feasibility in treating the human bile duct. The first encouraging results of 125 I seeds stent in the clinical setting were reported by Zhu et al 15 who's interim analysis showed that the 125 I seeds stent was safe and feasible in the treatment of MBO, and appeared to extend overall survival compared with the conventional stent (7.40 months versus 2.50 months).…”

Section: Discussionmentioning

confidence: 99%

Biliary self-expandable metallic stent combined with Iodine-125 seeds strand in the treatment of hilar malignant biliary obstruction

Zhou

Huang

et al. 2019

J Int Med Res

View full text Add to dashboard Cite

Objective: To assess the safety and effectiveness of a self-expandable metallic stent (SEMS) combined with Iodine-125 seeds strand to treat hilar malignant biliary obstruction (MBO). Methods: This retrospective study included patients who had received SEMS with 125 I seeds strand (seeds group) or SEMS alone (controls) to treat hilar MBO. Demographic, biochemical, stent patency, overall survival and complications data were extracted and analysed. Results: A total of 76 patients were included (seeds group, n ¼ 40; controls, n ¼ 36), with a total of 608 seeds deployed in the seeds group (mean, 15.2 AE 4.1 [range, 8-25] seeds per patient). Statistically significant between-group differences were shown in median stent patency time (seeds group, 387.0 AE 27.9 days [95% confidence interval {CI} 332.4, 441.6] versus controls, 121.0 AE 9.1 days [95% CI 103.2, 138.8]) and in median overall survival (seeds group, 177.0 AE 17.9 days [95% CI 141.8, 212.2] versus controls, 123.0 AE 20.4 [95% CI 83.0, 163.0]). There were no statistically significant between-group differences in complication rates. Conclusion: SEMS combined with 125 I seeds strand is safe, feasible, and tolerable in treating patients with hilar MBO, and may be effective in prolonging stent patency time and overall survival.

show abstract

“…Nowadays, interstitial implantation of 125 I seeds has been used to treat prostate cancer, and some other forms of recurrent or inoperable malignancies, such as non-small cell lung cancer, pancreatic cancer, and intracranial gliomas. [4][5][6][7][8] Previously, Ren et al 3 reported the use of 125 I seeds placed into the resected tumor bed of a patient with recurrent lumbar vertebral chondrosarcoma who underwent marginal resection. Although the pathology specimen was showed conventional low-grade chondrosarcoma, the treatment was effective, with no signs of recurrence at the 2-year follow-up.…”

Section: Introductionmentioning

confidence: 99%

Analysis of Cells Proliferation and MicroRNAs Expression Profile in Human Chondrosarcoma SW1353 Cells Exposed to Iodine-125 Seeds Irradiation

Zhu

et al. 2020

Dose-Response

View full text Add to dashboard Cite

Chondrosarcoma is the second most common bone malignancy in adults, and it is often resistant to traditional chemotherapy and radiation therapy. Permanent implantation of iodine-125 (125I) seeds has been explored for the treatment of many types of cancer. In this study, the aim was to investigate the proliferative and microRNA (miRNA) effects of 125I seeds irradiation on human chondrosarcoma SW1353 cells. First, a new in vitro 125I seed irradiation model was established, and cell viability and miRNA microarray assays were performed before and after exposure to the 125I seeds. Cell proliferation was inhibited, and miRNA expression was substantially altered by irradiation exposure. The inhibition of cell proliferation was positively correlated with increased radiation doses, with cells showing the highest total radiation dose 7 days after irradiation. A total of 2549 miRNAs were detected in the SW1353 cells after exposure to 6 Gy of radiation, which included 189 differentially expressed miRNAs (98 upregulated and 91 downregulated). Four miRNAs were found to play important roles in the inhibition of cell proliferation after irradiation exposure, including miR-1224-5p, miR-492, miR-135b-5p, and miR-6839-5p. The target genes of the associated miRNAs mentioned were vascular endothelial growth factor A ( VEGFA), C-X-C motif chemokine 12 ( CXCL12), mitogen-activated protein kinase kinase kinase kinase 3 ( MAP4K3), and apoptosis facilitator Bcl-2-like protein 14 ( BCL2L14). Hence, the mitogen-activated protein kinase signaling pathway may be involved in how chondrosarcoma cells respond to 125I seed irradiation.

show abstract

Effectiveness and safety of CT-guided 125I seed brachytherapy for postoperative locoregional recurrence in patients with non–small cell lung cancer

Cited by 28 publications

References 38 publications

Design and validation of a surgical navigation system for brachytherapy based on mixed reality

Design and validation of a surgical navigation system for brachytherapy based on mixed reality

Biliary self-expandable metallic stent combined with Iodine-125 seeds strand in the treatment of hilar malignant biliary obstruction

Analysis of Cells Proliferation and MicroRNAs Expression Profile in Human Chondrosarcoma SW1353 Cells Exposed to Iodine-125 Seeds Irradiation

Contact Info

Product

Resources

About